Why did TMD.TO stock spike pre-market?

The pre-market spike to **C$1.125** appears driven by low float and heavy trading volume (**117,220** shares). No confirmed earnings release was cited; always check company filings and news releases for verification.

What is Meyka AI’s view on TMD.TO stock?

Meyka AI gives TMD.TO a score of **68.74 (B, HOLD)**. The model flags mixed fundamentals, small market cap, and possible upside if Enos progresses. This is informational, not investment advice.

What are the main risks for Titan Medical (TMD.TO)?

Primary risks include regulatory delays, execution on product commercialisation, cash runway and dilution. Low liquidity can amplify price swings during volatile sessions.

How does Meyka AI forecast compare to current price?

Meyka AI's forecast model projects **C$1.85** in 12 months versus the current **C$1.125**, an implied upside of **64.44%**. Models are projections and not guarantees.

CA Stocks

TMD.TO Titan Medical TSX C$1.125 pre-market volume Mar11 2026: assess liquidity

ByHuzaifa Zahoor March 11, 2026March 11, 2026

TMD.TO stock opened pre-market sharply higher, trading at C$1.125 after an intraday move from C$0.05. Volume is elevated at 117,220 shares versus an average of 45,936, producing a relative volume of 2.55. The jump represents roughly 2,150.00% on the session and makes Titan Medical Inc. an immediate high-volume mover on the TSX. Investors should weigh the surge against the company’s small market cap of C$128,295,000 and limited free float.